This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WHEELAN D. SUTLIFF, M.D.; MAXWELL FINLAND, M.D.; THOMAS N. HUNNICUTT, M.D.

Arch Intern Med. 1933;51(3):435-446.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It has been suggested that the effects of specific serum therapy in type I lobar pneumonia are due, not to the specific antibodies contained in the serum, but to the nonspecific action of the intravenously administered horse serum proteins. Miller¹ and von den Velden,² as well as Hallermann and Kähler,³ have made this suggestion because of the symptomatic changes they noted in lobar pneumonia following the injection of protein materials other than immune horse serum, such as typhoid vaccine, normal horse serum and normal human serum. Sonnenfeld⁴ and Lichtenstein⁵ have supported this suggestion because they occasionally observed striking clinical improvement in patients with pneumonia due to pneumococci other than type I following the administration of serum that presumably contained only type I pneumococcic antibodies.

An examination of the question from the point of view of those who have had extended experience with the specific serum, . . . [Full Text PDF of this Article]

Author Affiliations
BOSTON

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital, and the Department of Medicine, Harvard Medical School.

Footnotes
This study was aided, in part, by the William W. Wellington Fund of the Harvard Medical School.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?